Please complete the CAPTCHA to continue
@t1dexchange.org
✓
20 phones found area 267, 815, 973, 303, 201, 215, 415, 650, 845, and 603
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
David Walton is listed as Chief Executive Officer at T1D Exchange at T1D Exchange, based in Greater Philadelphia, United States, United States. AeroLeads shows a work email signal at t1dexchange.org, phone signal with area code 267, 815, 973, 303, 201, 215, 415, 650, 845, 603, and a matched LinkedIn profile for David Walton.
David Walton previously worked as Chief Executive Officer at T1D Exchange and Board Member at T1D Exchange. David Walton holds Mba, Healthcare Management from The Wharton School.
This section adds company-level context without repeating David Walton's masked contact details.
AeroLeads found 1 current-domain work email signal for David Walton. Compare company email patterns before reaching out.
Executive in diabetes device / digital health / remote monitoring / population health. Over 25 years of healthcare industry experience, particularly in strategic planning, new product development, global product launches, marketing, analytics and business development. Nearly 25 years living with Type 1 Diabetes.
Listed skills include Product Launch, Medical Devices, Pharmaceutical Industry, Marketing Strategy, and 13 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Boston, MA, US
T1D Exchange is a nonprofit organization providing an array of real world evidence and research services in the diabetes arena. Our programs include managing a quality improvement collaborative of dozens of leading diabetes centers in the US, a direct to patient, online registry of more than 13,000 people living with Type 1 diabetes, and a team of.
Chronicare was acquired by QuiO in May 2019 as a digital health & remote monitoring company utilizing connected devices and digital engagement tools to improve medication adherence and outcomes in people with chronic disease. The initial offering focused on smart insulin pen caps and bluetooth glucose monitoring (BGM and CGM) to help optimize insulin use.
Salem, NH, US
Led all global commercial activities (sales, marketing, business development, project management) for AgaMatrix, a private medical device and diagnostics company that develops and manufactures blood glucose monitoring / mobile health products for people with diabetes.
Iselin, NJ, US
Led all global commercial planning and business development / partnership activities for Echo Therapeutics, a company developing a noninvasive, continuous glucose monitoring (CGM) system, initially for use in critically ill patients within the hospital. Also involved in corporate financing activities, including $35MM in equity financing in 2012-2013.
New Brunswick, NJ, US
Led global marketing planning for insulin delivery and continuous glucose monitoring business at Animas and LifeScan, including new product development, portfolio planning and global product and lifecycle management activities. Led global commercial launch of Animas Vibe (Dexcom CGM-enabled insulin pump) as well as several insulin pump and CGM reporting.
New Brunswick, NJ, US
Led commercial planning for multiple new products / indications in CNS and Oncology at McNeil Specialty Pharmaceuticals, including new indication in Adults for CONCERTA, a $1 Billion revenue product for treating Attention Deficit Hyperactivity Disorder.
New Brunswick, NJ, US
Managed various strategic planning projects for overall J&J Pharmaceuticals sector, as well as the Global Strategic Marketing organization (PGSM).
Worldwide, OO
Managed various healthcare strategy and operations projections, primarily in the managed care and healthcare delivery sectors. Clients included Kaiser Permanente, Blue Shield of California and Catholic Healthcare West.
Conducted various strategic planning, disease management and marketing strategy projects in pharmaceutical and biotech sectors. Clients included Pfizer, Genentech, Hoechst (now Sanofi-Aventis) and Smithkline Beecham (now Glaxo SmithKline).
Quick answers generated from the profile data available on this page.
David Walton works for T1D Exchange.
David Walton is listed as Chief Executive Officer at T1D Exchange at T1D Exchange.
AeroLeads has found 1 work email signal at @t1dexchange.org for David Walton at T1D Exchange.
AeroLeads has found 20 phone signal(s) with area code 267, 815, 973, 303, 201, 215, 415, 650, 845, 603 for David Walton at T1D Exchange.
David Walton is based in Greater Philadelphia, United States, United States while working with T1D Exchange.
David Walton has worked for T1D Exchange, Chronicare (Acquired By Quio), Agamatrix, Echo Therapeutics, and Johnson & Johnson.
You can use AeroLeads to view verified contact signals for David Walton at T1D Exchange, including work email, phone, and LinkedIn data when available.
David Walton holds Mba, Healthcare Management from The Wharton School.
David Walton is listed with skills including Product Launch, Medical Devices, Pharmaceutical Industry, Marketing Strategy, Strategic Planning, Global Marketing, Product Development, and Cross Functional Team Leadership.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts